Policy | May 25, 2021
Cipla to market Roche's Antibody Cocktail in India
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
Subscribe To Our Newsletter & Stay Updated
